Strategic alliances can benefit SMEs as well as Big Pharma, says CRO DZS

Strategic alliances can benefit SMEs as well as Big Pharma, says DZS

Strategic partnerships are “flexible, cost-effective and will become the trend over the next few years,” says CRO DZS, which has signed a multi-year deal with SBI Pharmaceuticals.

Parexel described strategic partnerships as “the next phase” in relations between contract research organisations (CROs) and sponsors last year, and a glut of deals between pharma and CROs help to demonstrate the trend.

However, whilst the focus has been on contracts between Big Pharma and Big CROs - such as Merck Serono and Quintiles, GSK and PPD, and Pfizer with Parexel and ICON - strategic partnerships can also benefit small and mid-sized companies, according to Greg Ambra, VP of Clinical Operations at DZS Clinical Services.

“DZS is still a relatively small CRO and there are many sponsors who may be in search for more traditional, well-known CROs,” he told Outsourcing-Pharma.com. “However, because of our size, flexibility, core expertise, and broad range of eClinical services, we feel there is an unmet need in the small to mid-size pharma and biotech category that we can serve.”

The New Jersey-based company has just signed a multi-year and multi-project contract with SBI Pharmaceuticals, granting the Japan-based pharma firm access to all its services and software at preferred pricing globally, but with particular focus in the MENA region.

“We see a shift towards more ‘creative’ partnerships driven by both biopharm sponsors and CROs,” Ambra said. “We feel partnerships which create stability, have a risk-sharing element to them, are flexible, cost-effective and will become the trend over the next few years.”

SBI opted to partner with DZS rather than sign the CRO up under a straight-forward provider contract was due to a number of factors, according to Ambra.

“We have facilitated enrollment with creative solutions, and implemented cost efficiencies which SBI has appreciated,” he said. Furthermore, the CRO’s management team and steering committee, set-up to oversee activities, identify risks, and resolve issues quickly, “led to strong feeling of ‘partnership’ which eventually led to [the] agreement.”

Related News

ISI Group downgrades Pfizer's two strategic CROs

ISI Group gets behind Quintiles while downgrading Pfizer's strategic partners ICON and Parexel

Small and mid-sized pharmas face a Catch-22 says Cromos CEO

Cromos offers free clinical trials to cash-strapped small and mid-sized pharmas

Citi Research survey finds CRO pricing has been flat, but expert says consolidation could lead to increase

Consolidation among small CROs could drive up prices, says analyst

The headquarters of privately-owned CRO PPD in Wilmington, North Carolina

Top CROs tight lipped about rumoured Pfizer deal

Addition of PPD will not affect ongoing business with Parexel and Icon, says Pfizer

Pfizer reveals PPD as third strategic CRO partner

Survey: Are strategic alliances good for the CRO industry?

Readers' Survey: Are strategic alliances good for the CRO industry?

Parexel and Theorem spoke with us at PCT, Vienna last week on strategic partnerships

Parexel: Strategic partnerships are reshaping the CRO industry

Chiltern says strategic deals are good for the CRO sector

Chiltern says strategic deals are good for the CRO sector

Strategic relationships are changing Pharma and CRO skillset says Parexel

Strategic relationships are changing Pharma and CRO skillset says Parexel

Pfizer teams with Parexel and Icon in CRO sector's latest strategic deals

Quintiles and Biogen Idec sign 5-year strategic deal

Biogen Idec selects Quintiles in 5-year strategic partnership

Sponsors and CROs talk strategic alliances at PCT in Vienna, Austria

Oversight is key in sponsor-CRO partnerships say Pfizer and Amgen

Advaxis selects inVentiv to conduct trials of immunotherapy candidates

Advaxis selects CRO inVentiv to conduct trials of immunotherapy candidates

Related Products

See more related products